|
340B Report investigated the impact of the Inflation Reduction Act and other federal policies on 340B savings. ICER’s President and CEO, Sarah K. Emond, MPP was interviewed for the piece:
“Multiple sources told 340B Report that the IRA’s Medicare Drug Price Negotiation Program has led some manufacturers to reduce list prices…Sarah Emond, president and CEO of the Institute for Clinical and Economic Review (ICER) a nonprofit healthcare economics research group that evaluates the cost-effectiveness of drugs and medical devices, said the policy does not mandate companies lower their WAC—it only sets a maximum price that Medicare is allowed to pay for the medicine. However, published MFPs give payers information for future negotiations on list prices, potentially making it more difficult for drugmakers to keep higher prices, Emond said.
Emond added that, theoretically, a drug company could reduce its WAC to lower the likelihood that its drug is selected for future IRA negotiations, since qualifying is based on gross spending.”
|